[go: up one dir, main page]

BR0010361A - Seq ências genÈmicas de neisseria e uso destas - Google Patents

Seq ências genÈmicas de neisseria e uso destas

Info

Publication number
BR0010361A
BR0010361A BR0010361-6A BR0010361A BR0010361A BR 0010361 A BR0010361 A BR 0010361A BR 0010361 A BR0010361 A BR 0010361A BR 0010361 A BR0010361 A BR 0010361A
Authority
BR
Brazil
Prior art keywords
neisseria
genetic sequences
sequences
proteins
genomic
Prior art date
Application number
BR0010361-6A
Other languages
English (en)
Inventor
Mariagrazia Pizza
Cesira Galeotti
Guido Grandi
Vega Masignani
Marirosa Mora
Rino Rappuoli
Giulio Ratti
Maria Scarselli
Claire M Frazer
Erin Hickey
Jeremy Peterson
Herve Tettelin
J Craig Venter
Vincenzo Scarlato
Original Assignee
Chiron Corp
Inst Genomic Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/023573 external-priority patent/WO2000022430A2/en
Priority claimed from GB0004695A external-priority patent/GB0004695D0/en
Application filed by Chiron Corp, Inst Genomic Research filed Critical Chiron Corp
Publication of BR0010361A publication Critical patent/BR0010361A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"SEQ êNCIAS GENÈMICAS DE NEISSERIA E USO DESTAS". A invenção fornece métodos de obtenção de proteínas imunogênicas a partir de sequências genómicas incluindo Neisseria, incluindo as seq³ências de aminoácido e as correspondentes seq³ências de nucleotídeo, assim como a seq³ência genómica de Neisseria meningitidis B. As proteínas desta forma obtidas são antígenos úteis para vacinas, composições imunogênicas e/ou diagnósticos.
BR0010361-6A 1999-04-30 2000-03-08 Seq ências genÈmicas de neisseria e uso destas BR0010361A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13206899P 1999-04-30 1999-04-30
PCT/US1999/023573 WO2000022430A2 (en) 1998-10-09 1999-10-08 Neisseria genomic sequences and methods of their use
GB0004695A GB0004695D0 (en) 2000-02-28 2000-02-28 Protein expression
PCT/US2000/005928 WO2000066791A1 (en) 1999-04-30 2000-03-08 Neisseria genomic sequences and methods of their use

Publications (1)

Publication Number Publication Date
BR0010361A true BR0010361A (pt) 2003-06-10

Family

ID=27255563

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010361-6A BR0010361A (pt) 1999-04-30 2000-03-08 Seq ências genÈmicas de neisseria e uso destas

Country Status (13)

Country Link
US (1) US20070219347A1 (pt)
EP (2) EP1185691B1 (pt)
JP (1) JP2003527079A (pt)
CN (2) CN101033467A (pt)
AT (1) ATE430207T1 (pt)
AU (1) AU780308B2 (pt)
BR (1) BR0010361A (pt)
CA (1) CA2371032A1 (pt)
DE (1) DE60042114D1 (pt)
DK (1) DK1185691T3 (pt)
ES (1) ES2323845T3 (pt)
MX (1) MXPA01011047A (pt)
WO (1) WO2000066791A1 (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1860192A1 (en) 1996-09-17 2007-11-28 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
WO1999057280A2 (en) 1998-05-01 1999-11-11 Chiron Corporation Neisseria meningitidis antigens and compositions
JP2004537956A (ja) 1999-01-22 2004-12-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規化合物
EP2270169A3 (en) 1999-03-12 2011-06-15 GlaxoSmithKline Biologicals SA Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
BR0010130A (pt) 1999-04-30 2002-06-04 Chiron Spa Antìgenos de neisseria conservados
EP2258851A1 (en) 1999-05-19 2010-12-08 Novartis Vaccines and Diagnostics S.r.l. Combination neisserial compositions
PT2275554E (pt) 1999-10-29 2015-06-26 Novartis Vaccines & Diagnostic Péptidos antigénicos de neisseria
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
RU2279889C2 (ru) 2000-01-17 2006-07-20 Чирон С.Р.Л. ВАКЦИНА ВЕЗИКУЛ НАРУЖНЫХ МЕМБРАН (OMV), СОДЕРЖАЩАЯ БЕЛКИ НАРУЖНОЙ МЕБРАНЫ N.Meningitidis СЕРОЛОГИЧЕСКОЙ ГРУППЫ В
US7947291B2 (en) * 2000-01-25 2011-05-24 The University Of Queensland Modified surface antigen
AU2001239478B2 (en) 2000-02-28 2007-05-17 Glaxosmithkline Biologicals S.A. Hybrid expression of neisserial proteins
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
US6936261B2 (en) 2000-07-27 2005-08-30 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0107219D0 (en) * 2001-03-22 2001-05-16 Microbiological Res Authority Immunogenic commensal neisseria sequences
GB0108024D0 (en) * 2001-03-30 2001-05-23 Chiron Spa Bacterial toxins
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
JP4592284B2 (ja) 2001-07-27 2010-12-01 カイロン ソチエタ ア レスポンサビリタ リミタータ 髄膜炎菌付着因子
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CA2479879A1 (en) * 2002-03-20 2003-10-02 Emory University Neisseria mutants, lipooligosaccharides and immunogenic compositions
DK1524993T3 (da) * 2002-08-02 2013-06-03 Glaxosmithkline Biolog Sa Neisseria-vaccinesammensætning omfattende en kombination af antigener
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US8663656B2 (en) 2002-10-11 2014-03-04 Novartis Ag Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
US7807802B2 (en) 2002-11-12 2010-10-05 Abbott Lab Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
ATE552844T1 (de) * 2003-01-30 2012-04-15 Novartis Ag Injizierbarer impfstoff gegen multiple meningokokken-serogruppen
CU23237A1 (es) * 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB1125 Y SU USO EN FORMULACIONES FARMACéUTICAS
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
JP2008529558A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 髄膜炎／敗血症に関連する大腸菌由来のタンパク質および核酸
CN101203529A (zh) 2005-02-18 2008-06-18 诺华疫苗和诊断公司 来自脑膜炎/脓毒症相关性大肠杆菌的蛋白质和核酸
EP1856291A4 (en) * 2005-03-04 2009-04-01 Verenium Corp NUCLEIC ACIDS AND PROTEINS, AND METHODS OF MAKING AND USING SAME
CU23578A1 (es) 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
CU23549A1 (es) * 2005-12-29 2010-07-20 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas que contienen la proteína nma0939
RU2450019C2 (ru) 2006-06-29 2012-05-10 Новартис Аг Полипептиды из neisseria meningitidis
CA2659552A1 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
CU23630A1 (es) 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
EP2245048B1 (en) 2008-02-21 2014-12-31 Novartis AG Meningococcal fhbp polypeptides
BRPI1009828A2 (pt) 2009-03-24 2019-03-12 Novartis Ag adjuvante de proteína de ligação de fator h meningocócica
AU2010247252A1 (en) 2009-05-14 2012-01-12 Sanofi Pasteur Method for admixing the lipopolysaccharide (LPS) of gram-negative bacteria
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
DK2608805T3 (en) 2010-08-23 2017-08-14 Wyeth Llc STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENES
WO2012032489A1 (en) 2010-09-10 2012-03-15 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
US9259462B2 (en) 2010-09-10 2016-02-16 Glaxosmithkline Biologicals Sa Developments in meningococcal outer membrane vesicles
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP2822583A2 (en) 2012-03-09 2015-01-14 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
ES2847923T3 (es) 2012-06-14 2021-08-04 Glaxosmithkline Biologicals Sa Vacunas contra el meningococo del serogrupo X
AU2013295242C1 (en) 2012-07-27 2018-08-09 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
BR112017017460A2 (pt) 2015-02-19 2018-04-10 Pfizer Inc. composições de neisseria meningitidis e métodos das mesmas
WO2017137085A1 (en) 2016-02-11 2017-08-17 Sanofi Pasteur Meningitidis vaccines comprising subtilinases
SG10202111092UA (en) 2017-01-31 2021-11-29 Pfizer Neisseria meningitidis compositions and methods thereof
CN110914441B (zh) * 2017-05-10 2024-06-28 环球生物能源公司 用于从3-甲基巴豆酸产生异丁烯的改进方法
US11464845B2 (en) 2017-07-21 2022-10-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neisseria meningitidis immunogenic compositions
US20220081707A1 (en) * 2018-07-25 2022-03-17 The Trustees Of Indiana University Diagnostic assay for a strain of neisseria meningitidis
CN113136444B (zh) * 2021-05-10 2024-04-19 临沂大学 医用食品中海氏肠球菌的微滴数字pcr检测方法
CN116162140A (zh) * 2022-07-19 2023-05-26 四川大学华西医院 一种幽门螺杆菌重组抗原蛋白SecG及其制备方法与应用
WO2025006737A1 (en) 2023-06-30 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2047043A1 (en) * 1990-07-19 1992-01-20 Allen I. Oliff Class ii protein of the outer membrane of neisseria meningitidis having immune enhancement properties
IE912559A1 (en) * 1990-07-19 1992-01-29 Merck & Co Inc The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same
CA2050635A1 (en) * 1990-07-19 1992-01-20 Allen I. Oliff Class ii protein of the outer membrane of neisseria meningitidis having immunologic carrier and enhancement properties, and vaccines containing same
AU5426098A (en) * 1996-10-24 1998-05-15 Emory University Invasion associated genes from (neisseria meningitidis) serogroup
JP2004511201A (ja) * 1998-10-09 2004-04-15 カイロン　コーポレイション ナイセリアゲノム配列およびそれらの使用方法

Also Published As

Publication number Publication date
ATE430207T1 (de) 2009-05-15
WO2000066791A1 (en) 2000-11-09
AU780308B2 (en) 2005-03-17
EP1185691A1 (en) 2002-03-13
CA2371032A1 (en) 2000-11-09
EP1605061A1 (en) 2005-12-14
US20070219347A1 (en) 2007-09-20
ES2323845T3 (es) 2009-07-27
DE60042114D1 (de) 2009-06-10
JP2003527079A (ja) 2003-09-16
EP1185691B1 (en) 2009-04-29
DK1185691T3 (da) 2009-06-22
MXPA01011047A (es) 2003-10-14
CN1359426A (zh) 2002-07-17
AU3249200A (en) 2000-11-17
CN101033467A (zh) 2007-09-12

Similar Documents

Publication Publication Date Title
BR0010361A (pt) Seq ências genÈmicas de neisseria e uso destas
MXPA01003557A (es) Secuencias genomicas de neisseria y metodos para su uso.
MXPA00010722A (es) Antigenos de neisseria meningitidis y composiciones que los contienen.
BR9906927A (pt) Proteìnas de neisseria meningitidis
WO2001031019A3 (en) Neisserial antigenic peptides
CY1110880T1 (el) Αντιγονα neisserial
CY1109268T1 (el) Αλληλουχιες γονιδιωματος της neisseria και μεθοδοι για την χρηση τους

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: THE INSTITUTE FOR GENOMIC RESEARCH (US) , NOVARTIS

Free format text: ALTERADO DE: CHIRON CORPORATION

B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B15V Prolongation of time limit allowed

Free format text: RECONHECIDO O OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 28 DIAS, NOS TERMOS DO ARTIGO 221 PARAGRAFO 2O DA LPI E DA RESOLUCAO 116/04.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O ART. 24, ART. 10 E ART. 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.